SCHEMBL29411752

SCHEMBL29411752

C[Si](C)(C)c1cc(C=O)cc(C(=O)O)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UNG P13051 1/20 0.47
ALDH1A1 P00352 2/20 0.44
HPGD P15428 2/20 0.38
TPMT P51580 3/20 0.38
TRIM24 O15164 1/20 0.38
TRIM33 Q9UPN9 1/20 0.38
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
HIF1A Q16665 1/20 0.36
KDM4E B2RXH2 2/20 0.35
POLB P06746 1/20 0.35
HTT P42858 1/20 0.35
CASP6 P55212 1/20 0.35
CTDSP1 Q9GZU7 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CA12 O43570 3/20 0.34
CA1 P00915 3/20 0.34
CA2 P00918 3/20 0.34
CA7 P43166 3/20 0.34
CA9 Q16790 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2897282 0.82 HPGD (0.48) ALDH1A1HPGDTPMTALOX15TSHR
SCHEMBL5833655 0.82 HPGD (0.48) ALDH1A1HPGDTPMTALOX15TSHR
SCHEMBL16434649 0.80 UNG (0.61) UNGALDH1A1HPGDTPMTTRIM24
SCHEMBL3470017 0.80 UNG (0.61) UNGALDH1A1HPGDTPMTTRIM24
SCHEMBL1174923 0.75 TPMT (0.64) UNGALDH1A1HPGDTPMTTRIM24
SCHEMBL15426747 0.75 UNG (0.52) UNGALDH1A1HPGDTPMTTRIM24
SCHEMBL17049785 0.74 UNG (0.55) UNGALDH1A1HPGDTPMTTRIM24
SCHEMBL17049781 0.74 UNG (0.55) UNGALDH1A1HPGDTPMTTRIM24
SCHEMBL18267471 0.72 CA12 (0.62) UNGALDH1A1HPGDTRIM24TRIM33
SCHEMBL17167118 0.72 UNG (0.53) UNGALDH1A1HPGDTPMTTRIM24

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4733297-A1 INTEGRIN-INHIBITING SMALL MOLECULE COMPOUND Antibody Therapeutics, Inc. (JP) 2026-04-29 EP disclosed
WO-2024262620-A1 INTEGRIN-INHIBITING SMALL MOLECULE COMPOUND 株式会社抗体医学研究所 2024-12-26 WO disclosed
EP-3960750-B1 PHOTOSENSITIZING AGENT, AND FLUORESCENT PROBE COMPOSITION M T 3 INC (JP) 2023-05-24 EP disclosed
US-11643430-B2 Porphyrin compound or salt thereof, cancer therapeutic agent, photosensitizer, and fluorescent probe M.T.3, INC. (JP) 2023-05-09 US disclosed
US-20220064203-A1 COMPOUND OR SALT THEREOF, AND METHOD M.T.3, INC. (JP) 2022-03-03 US disclosed
EP-3960750-A1 COMPOUND OR SALT THEREOF, CANCER TREATMENT AGENT, PHOTOSENSITIZING AGENT, AND FLUORESCENT PROBE COMPOSITION M.T.3, Inc. (JP) 2022-03-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220064203-A1 COMPOUND OR SALT THEREOF, AND METHOD RER1, REN, RDX UNG 4789/4885ALDH1A1 3061/4885HPGD 2363/4885
US-11643430-B2 Porphyrin compound or salt thereof, cancer therapeutic agent, photosensitizer, and fluorescent probe PPOX, RB1, HCCS UNG 4448/4885ALDH1A1 3324/4885HPGD 1522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.